TY - JOUR
T1 - Glial degeneration with oxidative damage drives neuronal demise in mpsii disease
AU - Zalfa, Cristina
AU - Verpelli, Chiara
AU - D’avanzo, Francesca
AU - Tomanin, Rosella
AU - Vicidomini, Cinzia
AU - Cajola, Laura
AU - Manara, Renzo
AU - Sala, Carlo
AU - Scarpa, Maurizio
AU - Vescovi, Angelo Luigi
AU - De Filippis, Lidia
N1 - Funding Information:
Acknowledgements. We thank Elena Fusar Poli and Alessio Giavazzi for Iba1 and PECAM immunostaining. Human tissue was obtained from the NIHCD Brain and Tissue Bank for Developmental Disorders at the University of Maryland. The role of NIHCD Brain and Tissue Bank is to distribute tissue, and therefore cannot endorse the studies performed or the interpretation of results. The project was funded by the following foundations: Cellule Staminali di Terni, Revert Onlus, Assicurazioni Generali Trieste and Brains for Brain (http://www.brains4brain.eu). CS was supported by PNR-CNR Aging Program 2012–2014 and by the foundations: Comitato Telethon Onlus, CARIPLO and Jerome Lejeune. CV was supported by the Foundation CARIPLO.
Publisher Copyright:
© The Author(s) 2016.
PY - 2016
Y1 - 2016
N2 - Mucopolysaccharidosis type II (MPSII) is a lysosomal storage disorder due to the deficit of the iduronate 2-sulfatase (IDS) enzyme, causing progressive neurodegeneration in patients. Neural stem cells (NSCs) derived from the IDS-ko mouse can recapitulate MPSII pathogenesis in vitro. In differentiating IDS-ko NSCs and in the aging IDS-ko mouse brain, glial degeneration precedes neuronal degeneration. Here we show that pure IDS-ko NSC-derived astrocytes are selectively able to drive neuronal degeneration when cocultured with healthy neurons. This phenotype suggests concurrent oxidative damage with metabolic dysfunction. Similar patterns were observed in murine IDS-ko animals and in human MPSII brains. Most importantly, the mutant phenotype of IDS-ko astrocytes was reversed by low oxygen conditions and treatment with vitamin E, which also reversed the toxic effect on cocultured neurons. Moreover, at very early stages of disease we detected in vivo the development of a neuroinflammatory background that precedes astroglial degeneration, thus suggesting a novel model of MPSII pathogenesis, with neuroinflammation preceding glial degeneration, which is finally followed by neuronal death. This hypothesis is also consistent with the progression of white matter abnormalities in MPSII patients. Our study represents a novel breakthrough in the elucidation of MPSII brain pathogenesis and suggests the antioxidant molecules as potential therapeutic tools to delay MPSII onset and progression.
AB - Mucopolysaccharidosis type II (MPSII) is a lysosomal storage disorder due to the deficit of the iduronate 2-sulfatase (IDS) enzyme, causing progressive neurodegeneration in patients. Neural stem cells (NSCs) derived from the IDS-ko mouse can recapitulate MPSII pathogenesis in vitro. In differentiating IDS-ko NSCs and in the aging IDS-ko mouse brain, glial degeneration precedes neuronal degeneration. Here we show that pure IDS-ko NSC-derived astrocytes are selectively able to drive neuronal degeneration when cocultured with healthy neurons. This phenotype suggests concurrent oxidative damage with metabolic dysfunction. Similar patterns were observed in murine IDS-ko animals and in human MPSII brains. Most importantly, the mutant phenotype of IDS-ko astrocytes was reversed by low oxygen conditions and treatment with vitamin E, which also reversed the toxic effect on cocultured neurons. Moreover, at very early stages of disease we detected in vivo the development of a neuroinflammatory background that precedes astroglial degeneration, thus suggesting a novel model of MPSII pathogenesis, with neuroinflammation preceding glial degeneration, which is finally followed by neuronal death. This hypothesis is also consistent with the progression of white matter abnormalities in MPSII patients. Our study represents a novel breakthrough in the elucidation of MPSII brain pathogenesis and suggests the antioxidant molecules as potential therapeutic tools to delay MPSII onset and progression.
UR - http://www.scopus.com/inward/record.url?scp=85019859464&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019859464&partnerID=8YFLogxK
U2 - 10.1038/cddis.2016.231
DO - 10.1038/cddis.2016.231
M3 - Article
C2 - 27512952
AN - SCOPUS:85019859464
SN - 2041-4889
VL - 7
JO - Cell Death and Disease
JF - Cell Death and Disease
IS - 8
M1 - e2331
ER -